Insmed’s brensocatib drug showed promising results in a pivotal clinical trial for non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease with no FDA-approved therapies. The drug significantly reduced pulmonary exacerbations and was well-tolerated by patients. Leerink Partners analyst Joseph Schwartz noted a potential market opportunity of 450,000 patients in the U.S. alone for NCFB treatment. The success of brensocatib in NCFB has opened the door for additional indications, including chronic rhinosinusitis and hidradenitis suppurativa. Insmed plans to submit a new drug application to the FDA later this year, potentially leading to a launch by mid-2025. AstraZeneca, the original developer of the drug, stands to benefit from milestone payments and royalties.
Source link
Insmed’s Trial Results Pave Way for FDA Filing in a Lung Disease With No Approved Therapies
